Optimi Health Corp Dossier
Qualitative Analysis
Business overview
Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI, FSE: 8BN0) is a commercial-stage pharmaceutical manufacturer licensed by Health Canada for the production and distribution of GMP-grade psychedelic drug products. The company specializes in controlled substances, specifically manufacturing validated MDMA capsules and botanical psilocybin extracts at its vertically integrated, 20,000-square-foot GMP-compliant facilities in Princeton, British Columbia. Optimi operates primarily as a business-to-business supplier, providing active pharmaceutical ingredients (APIs) and finished dosage forms to regulated clinical trials, research organizations, and therapeutic programs globally. Its products are commercially prescribed to patients in Australia under the Therapeutic Goods Administration's (TGA) Authorized Prescriber Scheme and are accessible in Canada through the Special Access Program.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of naturally derived ibogaine in hydrochloride (HCl) and freebase forms.
Expected impact: Establishes Optimi as a reliable, GMP-grade supplier of ibogaine (50mg and 100mg capsules) for global research institutions and regulated patient access programs.
Scaling the supply of GMP-certified MDMA and natural psilocybin extract capsules to authorized clinics under Australia's Authorized Prescriber Scheme.
Expected impact: Drives near-term product revenue and establishes early-mover commercial validation in the world's first nationally regulated psychedelic medicine market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Facilitates the distribution of Optimi's MDMA and psilocybin capsules through a lead pharmaceutical distribution company and registered pharmacy networks across Australia.
Terms: Optimi acts as the exclusive Canadian supplier of GMP-certified MDMA and psilocybin capsules, with Mind Medicine Australia overseeing local distribution and patient coordination.
Optimi supplies its GMP psilocybin extract capsules for a Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD) in 200 patients.
Terms: Supply agreement to provide capsules for the trial starting in 2025, with ongoing collaboration on a Phase 3 trial submission in Canada.
Optimi was selected to supply GMP 40mg and 60mg MDMA capsules for MAPS Israel's Healing October 7th project, a clinical trial for PTSD approved by the Israeli Ministry of Health.
Terms: Optimi completed the export of MDMA capsules to support the open-label study of 168 participants sponsored by Sheba Medical Center.